These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22380653)

  • 1. Lead optimization of 17β-HSD1 inhibitors of the (hydroxyphenyl)naphthol sulfonamide type for the treatment of endometriosis.
    Henn C; Einspanier A; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    J Med Chem; 2012 Apr; 55(7):3307-18. PubMed ID: 22380653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.
    Marchais-Oberwinkler S; Wetzel M; Ziegler E; Kruchten P; Werth R; Henn C; Hartmann RW; Frotscher M
    J Med Chem; 2011 Jan; 54(2):534-47. PubMed ID: 21189020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1.
    Spadaro A; Frotscher M; Hartmann RW
    J Med Chem; 2012 Mar; 55(5):2469-73. PubMed ID: 22277094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases.
    Oster A; Hinsberger S; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    J Med Chem; 2010 Nov; 53(22):8176-86. PubMed ID: 20977238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of an electron withdrawing group on the hydroxyphenylnaphthol scaffold improves the potency of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors.
    Wetzel M; Marchais-Oberwinkler S; Perspicace E; Möller G; Adamski J; Hartmann RW
    J Med Chem; 2011 Nov; 54(21):7547-57. PubMed ID: 21972996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
    Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
    Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
    Starcević S; Brozic P; Turk S; Cesar J; Rizner TL; Gobec S
    J Med Chem; 2011 Jan; 54(1):248-61. PubMed ID: 21138273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
    Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
    Al-Soud YA; Bey E; Oster A; Marchais-Oberwinkler S; Werth R; Kruchten P; Frotscher M; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):212-5. PubMed ID: 18848601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
    Oster A; Klein T; Henn C; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    ChemMedChem; 2011 Mar; 6(3):476-87. PubMed ID: 21337522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for species specific inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): computational study and biological validation.
    Klein T; Henn C; Negri M; Frotscher M
    PLoS One; 2011; 6(8):e22990. PubMed ID: 21857977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
    Xu K; Al-Soud YA; Wetzel M; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2011 Dec; 46(12):5978-90. PubMed ID: 22037253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC
    Abdelsamie AS; van Koppen CJ; Bey E; Salah M; Börger C; Siebenbürger L; Laschke MW; Menger MD; Frotscher M
    Eur J Med Chem; 2017 Feb; 127():944-957. PubMed ID: 27852458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
    Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
    J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
    Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.